Symbols

ACHV

Achieve Life·NASDAQ

--(--)

ACHV fundamentals

ACHV Q4 2025 Earnings

Achieve Life (ACHV) released its earnings on Mar 24, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.28 (YoY +22.22%), beat estimates.

Revenue / YoY

EPS / YoY

-0.28

+22.22%

Report date

Mar 24, 2026

ACHV Earnings Call Summary for Q4,2025

FDA Milestones: NDA for smoking cessation under review with June 2026 PDUFA date; vaping indication on accelerated 1-2 month review track.
Commercial Readiness: U.S. manufacturing partnership with Adea Pharma; 3PL and specialty pharmacy infrastructure 90% complete for Q2 2027 launch.
Clinical Strength: Phase III data shows 75% adherence and consistent efficacy across treatment-resistant smokers; vaping trial recruitment underway.
Market Opportunity: 25M smokers and 18M vapers with no FDA-approved vaping cessation treatment; ISO report recommends immediate coverage post-approval.
Financial Position: $36.4M cash balance; evaluating financing to support launch and scale.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Achieve Life (ACHV) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Achieve Life (ACHV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Achieve Life (ACHV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Achieve Life (ACHV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown